Archived Screening Performance Benchmarks 2007-2013

ARCHIVED Performance Benchmarks for Screening Mammography

In the United States, a Food and Drug Administration (FDA) regulation requires limited auditing of clinical outcomes for screening and diagnostic mammography examinations that have been assessed as suspicious for or highly suggestive of malignancy. More comprehensive auditing is performed by many mammography facilities in the United States and other countries. Auditing is thought to be a useful quality assurance procedure, providing performance feedback to mammography facilities and interpreting radiologists.

The following tables and figures contain a range of performance measures pertinent to the comprehensive  auditing of screening mammograms. Pooled data from BCSC registries provides by far the largest reported experience of U.S. screening mammography practice, from which reasonable and realistic screening benchmarks may be derived.

Updated screening performance benchmarks using data from 2011-2018 can be found here

Note: Lobular carcinoma in situ (LCIS) diagnoses have been excluded from these performance measures.

Tables & Figures

The archived estimates are based on 1,682,504 screening mammograms performed between 2007 and 2013.

Screening Performance Benchmark Publications

Please also see the following BCSC screening performance benchmarks publications related to the data presented above: 

Lehman CD, Arao RF, Sprague BL, Lee JM, Buist DS, Kerlikowske K, Henderson LM, Onega T, Tosteson AN, Rauscher GH, Miglioretti DL. National Performance Benchmarks for Modern Screening Digital Mammography: Update from the Breast Cancer Surveillance Consortium. Radiology 2017;283(1):49–58. [Abstract or Full Text]

Rosenberg RD, Yankaskas BC, Abraham LA, Sickles EA, Lehman CD, Geller BM, Carney PA, Kerlikowske K, Buist DS, Weaver DL, Barlow WE, Ballard-Barbash R. Performance benchmarks for screening mammography. Radiology 2006 Oct;241(1):55-66. [Abstract]